Company Filing History:
20 out of 8,684 
2 out of 16,080 Years Active: 1991-2020
Title: Mark A Guelta: A Pioneer in Mutant Enzyme Patents
Introduction:
In the world of scientific research and innovation, Mark A Guelta, hailing from White Marsh, MD in the United States, has made significant contributions to the field. With an impressive portfolio of 22 patents and a focus on mutant enzymes, Guelta has revolutionized the degradation of dangerous chemical compounds. This article delves into his latest patents, career highlights, collaborations, and the impact of his groundbreaking inventions.
Latest Patents:
Guelta's recent patents demonstrate his expertise in creating mutant enzymes with increased catalytic efficiency on specific chemical agents. One notable invention involves the development of mutant OPAA enzymes that effectively degrade cylcosarin (GF) - a potent chemical warfare agent. These enzymes surpass the catalytic efficiency of the wild-type OPAA, offering potential applications in neutralizing harmful substances.
Another groundbreaking patent involves mutant organophosphorus acid anhydrolase enzymes capable of degrading toxic V-agent compounds such as VX, VR, CVX, and VM. By incorporating multiple site mutations, these enzymes exhibit enhanced catalytic efficiency, paving the way for improved methods of neutralizing hazardous chemical threats.
Career Highlights:
Guelta's career boasts an illustrious association with prestigious institutions. He has collaborated with the esteemed organization, The United States of America As Represented by the Secretary of the Navy, where he has made significant contributions to the advancement of the field. Additionally, his work with The United States of America, As Represented by the Secretary of, has further solidified his position as a pioneer in enzyme research.
Collaborations:
Collaboration is an integral part of any innovative journey, and Guelta has partnered with notable individuals in his domain. Working alongside Hugh R Carlon and Steven P Harvey, Guelta has combined their collective expertise to push the boundaries of enzyme engineering and its applications. These collaborations have undoubtedly played a pivotal role in his success.
Conclusion:
Mark A Guelta's impressive portfolio of 22 patents and his dedication to mutant enzyme research highlight his commitment to innovation in the field of chemical compounds degradation. His latest inventions in mutant OPAA enzymes and organophosphorus acid anhydrolases demonstrate his profound impact on enhancing the catalytic efficiency of enzymes. Guelta's collaborations with esteemed organizations and individuals further testify to his contributions to the scientific community. As he continues to break new ground, Guelta is poised to shape the future of enzyme engineering and revolutionize the methods of neutralizing dangerous chemical agents.